Literature DB >> 647628

Decreased monocyte function in patients with Hodgkin's disease.

L Leb, J A Merritt.   

Abstract

Monocyte function in nine untreated and nine treated patients with Hodgkin's disease in different stages was studied simultaneously with normal controls. Monocyte chemotactic responses were decreased in 6 of the 14 patients with advanced disease regardless of previous therapy. None of our patients with stage II disease had abnormal results. Decreased monocyte chemotactic responses correlated with the presence of cutaneous anergy. In addition, decreased chemotaxis was associated with diminished monocyte bactericidal activity. This suggests that decreased bactericidal activity may be related to abnormal migration and possible diminished ingestion. The data support the hypothesis that depressed monocyte function may contribute to the increased susceptibility to infections of patients with Hodgkin's disease and it may be an additional factor favoring tumor dissemination in the advanced stages of the disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647628     DOI: 10.1002/1097-0142(197805)41:5<1794::aid-cncr2820410522>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  [Hodgkin's disease. Results in diagnosis and treatment (author's transl)].

Authors:  D Huhn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-04-17

2.  Pathophysiological aspects of Hodgkin's disease.

Authors:  D Huhn
Journal:  Klin Wochenschr       Date:  1979-05-16

Review 3.  Disordered function of mononuclear phagocytes in malignant disease.

Authors:  R J Sokol; G Hudson
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

4.  Morphometry of blood monocytes in malignant lymphoma.

Authors:  R J Sokol; G Hudson; J Wales; N T James
Journal:  J Clin Pathol       Date:  1985-08       Impact factor: 3.411

5.  Potentiation of the defective monocyte chemotaxis in Hodgkin's disease by in vitro tuftsin treatment.

Authors:  K Lukács; E Berényi; M Kávai; G Szegedi; M Szekerke
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.

Authors:  J Passwell; M Levanon; J Davidsohn; B Ramot
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

7.  Monocyte function in Hodgkin's disease.

Authors:  G Holm; M Björkholm; B Johansson; H Mellstedt; C Lindemalm
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

8.  Increased luminol-enhanced chemiluminescence of blood monocytes and granulocytes in Hodgkin's disease.

Authors:  O Tullgren; R Giscombe; G Holm; B Johansson; H Mellstedt; M Björkholm
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

9.  [Adenosine deaminase activity in Hodgkin's disease (author's transl)].

Authors:  G Müller; K Krug; W Krüger; V Richter; F Rassoul
Journal:  Klin Wochenschr       Date:  1982-03

10.  Increased monocyte-mediated antibody-dependent cellular cytotoxicity (ADCC) in Hodgkin's disease.

Authors:  H Pehamberger; H Ludwig; P Pötzi; W Knapp
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.